相关实验视频

Updated: Jun 28, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

瓦洛克托基因罗克萨帕尔沃维克和预防性第八因子替代剂在严重血友病A的比较有效性

Johannes Oldenburg¹, Herve Chambost², Hai Liu³

¹Institute of Experimental Haematology and Transfusion Medicine and Center for Rare Diseases, University Hospital Bonn, Bonn, Germany. johannes.oldenburg@ukbonn.de.

Advances in therapy

|April 14, 2024

概括

与第八因子预防相比,Valoctocogene roxaparvovec基因疗法显著降低了严重血友病A患者的出血率. 更多的患者通过基因疗法实现了零出血,证明了它的有效性.

科学领域:

血液学血液学血液学
基因治疗基因治疗
临床试验临床试验

背景情况:

严重血友病A (SHA) 是一种严重的出血障碍.
目前的标准护理包括预防性因子VIII (FVIII) 输注.
瓦洛克托基因roxaparvovec是一种用于SHA的试验性基因疗法.

研究的目的:

为了比较 valoctocogene roxaparvovec 与 SHA 患者的 FVIII 预防的有效性.
评估出血率和实现零出血的患者比例.

主要方法:

一项后期分析比较了112名接受valoctocogene roxaparvovec (GENEr8-1试验) 的患者和73名接受FVIII预防的患者 (研究270-902).
倾向性评分 (PS) 和标准化死亡率加权被用于调整基线差异.
年化出血率 (ABR) 和零出血患者的比例进行了比较.

主要成果:

PS调整成功地减少了群体之间的基线特征差异.
与FVIII预防治疗相比,瓦洛克托科根罗沙帕罗维克治疗导致治疗平均ABR (0.85比4.40) 和所有ABR (1.54比5.01) 显著降低.
显著更高的比例的患者在基因治疗中实现了零治疗出血 (82.1%对32.9%) 和零全部出血 (58.0%对28.5%).

结论:

与SHA患者的FVIII预防相比,Valoctocogene roxaparvovec表现出更高的有效性.
基因疗法导致出血事件大幅减少,并增加了没有出血的患者.
这些发现支持valoctocogene roxaparvovec作为严重血友病A的潜在新治疗选择.

关键词:

临床试验临床试验是指临床试验的临床试验.第八个因子基因治疗是一种基因疗法.血友病A型血友病A型血友病倾向性得分倾向性得分瓦洛克托科基因 (Valoctocogene) 是一种具有强度的蛋白质.

更多相关视频

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...